## **Giuseppe Gargiulo**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286137/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	6.3	555
2	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, The, 2019, 394, 1335-1343.	6.3	465
3	Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. European Heart Journal, 2017, 38, 2948-2956.	1.0	383
4	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal, 2019, 40, 3757-3767.	1.0	211
5	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
6	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention, 2020, 16, 371-379.	1.4	132
7	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ, The, 2015, 351, h5392.	3.0	102
8	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2016, 165, 334.	2.0	102
9	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2021. 42. 308-319.	1.0	90
10	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. European Heart Journal, 2020, 41, 3743-3749.	1.0	89
11	Cerebral Embolic Lesions Detected With Diffusion-Weighted Magnetic Resonance Imaging Following Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2014, 7, 1177-1183.	1.1	80
12	Early discharge after transfemoral transcatheter aortic valve implantation. Heart, 2015, 101, 1485-1490.	1.2	80
13	A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, e1047-e1056.	1.4	80
14	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A metaâ€analysis of 5,971 patients. Catheterization and Cardiovascular Interventions, 2015, 86, 518-527.	0.7	75
15	Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovascular Diabetology, 2020, 19, 76.	2.7	75
16	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002220.	1.4	73
17	A Critical Appraisal of Aspirin in Secondary Prevention. Circulation, 2016, 134, 1881-1906.	1.6	70
18	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute CoronaryÂSyndromes. Journal of the American College of Cardiology, 2021, 77, 375-388.	1.2	70

#	Article	IF	CITATIONS
19	EGFR trans-activation by urotensin II receptor is mediated by Î <sup>2</sup> -arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	2.5	68
20	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. JAMA Cardiology, 2016, 1, 795.	3.0	68
21	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
22	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 253-262.	0.4	66
23	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	63
24	Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2014, 114, 875-882.	0.7	60
25	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Annals of Internal Medicine, 2017, 167, 17.	2.0	56
26	Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and low ejection fraction: A meta-analysis of 6898 patients. International Journal of Cardiology, 2014, 176, 32-39.	0.8	54
27	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. American Heart Journal, 2016, 174, 95-102.	1.2	53
28	Genetic Deletion of Uncoupling Protein 3 Exaggerates Apoptotic Cell Death in the Ischemic Heart Leading to Heart Failure. Journal of the American Heart Association, 2013, 2, e000086.	1.6	50
29	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ, The, 2016, 355, i5483.	3.0	48
30	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. EuroIntervention, 2015, 11, 690-697.	1.4	48
31	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. JACC: Cardiovascular Interventions, 2018, 11, 36-50.	1.1	47
32	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention, 2021, 17, e898-e909.	1.4	45
33	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. American Journal of Cardiology, 2016, 118, 1888-1896.	0.7	37
34	Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 119, 308-316.	0.7	37
35	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. EuroIntervention, 2017, 13, 717-733.	1.4	37
36	<i>Akap1</i> Regulates Vascular Function and Endothelial Cells Behavior. Hypertension, 2018, 71, 507-517.	1.3	33

#	Article	IF	CITATIONS
37	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the <scp>GHOST</scp> registry. Catheterization and Cardiovascular Interventions, 2015, 85, 1150-1161.	0.7	32
38	New Cerebral Lesions at Magnetic Resonance Imaging after Carotid Artery Stenting Versus Endarterectomy: An Updated Meta-Analysis. PLoS ONE, 2015, 10, e0129209.	1.1	32
39	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 66, 1639-1640.	1.2	32
40	Bivalirudin or Heparin in Patients Undergoing Invasive Management of AcuteÂCoronaryÂSyndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	1.2	32
41	Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1983-H1989.	1.5	31
42	Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. International Journal of Cardiology, 2013, 167, 2566-2571.	0.8	27
43	Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation. Cardiovascular Research, 2015, 107, 431-441.	1.8	27
44	Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. Current Vascular Pharmacology, 2014, 12, 106-116.	0.8	26
45	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	1.1	26
46	Induction of Mitogen-Activated Protein Kinases Is Proportional to the Amount of Pressure Overload. Hypertension, 2010, 55, 137-143.	1.3	24
47	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. International Journal of Cardiology, 2016, 203, 264-266.	0.8	24
48	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	1.4	24
49	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	0.6	23
50	Impact of Sex on 2-Year Clinical OutcomesÂin Patients Treated WithÂ6-Month or 24-Month Dual-Antiplatelet Therapy Duration. JACC: Cardiovascular Interventions, 2016, 9, 1780-1789.	1.1	23
51	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	1.6	23
52	Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention, 2015, 14, W92-W95.	1.4	23
53	Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies. International Journal of Cardiology, 2015, 195, 79-81.	0.8	22
54	Post-Procedural Bivalirudin Infusion atÂFull or Low Regimen in Patients WithÂAcute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 73, 758-774.	1.2	22

#	Article	IF	CITATIONS
55	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention, 2017, 13, 78-86.	1.4	21
56	Impact of chronic kidney disease on 2â€year clinical outcomes in patients treated with 6â€month or 24â€month DAPT duration: An analysis from the PRODIGY trial. Catheterization and Cardiovascular Interventions, 2017, 90, E73-E84.	0.7	18
57	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 120, 2025-2030.	0.7	18
58	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 810-822.	2.2	18
59	Use of statins in lower extremity artery disease: a review. BMC Surgery, 2012, 12, S15.	0.6	17
60	Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. Journal of Cardiovascular Medicine, 2016, 17, 524-529.	0.6	17
61	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 475-486.	0.4	15
62	Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2016, 17, 803-818.	0.9	14
63	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. American Journal of Cardiology, 2018, 122, 6-11.	0.7	13
64	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. EuroIntervention, 2021, 17, e971-e980.	1.4	13
65	Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication. BMC Surgery, 2012, 12, S19.	0.6	11
66	Renal dysfunction and transcatheter aortic valve implantation outcomes. Expert Review of Cardiovascular Therapy, 2016, 14, 1315-1323.	0.6	11
67	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. International Journal of Cardiology, 2018, 260, 42-46.	0.8	11
68	Radial versus femoral access for cardiac catheterisation – Authors' reply. Lancet, The, 2015, 386, 2394.	6.3	10
69	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. Journal of Cardiovascular Medicine, 2020, 21, 660-666.	0.6	10
70	Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. Seminars in Thrombosis and Hemostasis, 2021, 47, 950-961.	1.5	10
71	New-Onset Coronary Aneurism and Late-Acquired Incomplete Scaffold Apposition After Full Polymer Jacket ofÂaÂChronic Total Occlusion With Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2015, 8, e41-e43.	1.1	9
72	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. Journal of Cardiovascular Medicine, 2016, 17, 843-849.	0.6	9

#	Article	IF	CITATIONS
73	Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. Journal of Thoracic Disease, 2017, 9, 4260-4265.	0.6	9
74	Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study. Cardiovascular Diabetology, 2017, 16, 7.	2.7	7
75	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. Journal of Electrocardiology, 2019, 57, 44-54.	0.4	7
76	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 893-901.	0.4	7
77	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research. 2021. 14. 110-119.	1.1	7
78	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. EuroIntervention, 2016, 12, e152-e159.	1.4	7
79	Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes. Frontiers in Cardiovascular Medicine, 2015, 2, 13.	1.1	6
80	Prevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network. International Journal of Cardiology, 2015, 184, 417-419.	0.8	6
81	Femoral Access With or Without Vascular Closure Device or RadialÂAccess in Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2019, 12, 2116-2118.	1.1	6
82	Consolidating the value of the standardised ARC-HBR definition. EuroIntervention, 2021, 16, 1126-1128.	1.4	6
83	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 189, 77-78.	0.8	5
84	Bivalirudin in Current Practice. JACC: Cardiovascular Interventions, 2016, 9, 1321-1323.	1.1	5
85	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. JACC: Cardiovascular Imaging, 2016, 9, 210-211.	2.3	5
86	To EncourAGE Individualized DualÂAntiplatelet Therapy Duration AfterÂDrug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2018, 11, 444-447.	1.1	5
87	Lugar de acceso y tipo de anticoagulante en pacientes con sÃndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria. Revista Espanola De Cardiologia, 2020, 73, 893-901.	0.6	5
88	Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. EuroIntervention, 2021, 16, e1245-e1253.	1.4	5
89	Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. Journal of Thrombosis and Thrombolysis, 2022, 53, 495-498.	1.0	5
90	Balancing hemorrhagic and thrombotic complications in a patient with a very late paclitaxel-eluting stent thrombosis: a clinical case report. Journal of Cardiovascular Medicine, 2011, 12, 366-369.	0.6	4

#	Article	IF	CITATIONS
91	Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Current Cardiology Reports, 2017, 19, 2.	1.3	4
92	Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1046-1049.	1.1	4
93	Complete Revascularization in Acute and Chronic Coronary Syndrome. Cardiology Clinics, 2020, 38, 491-505.	0.9	4
94	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1170-1179.	0.4	4
95	Unexpected preserved brain perfusion imaging despite severe and diffuse atherosclerosis of supra-aortic trunks : case report - online article. Cardiovascular Journal of Africa, 2013, 24, e12-e14.	0.2	4
96	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	1.6	4
97	Embolic protection devices during carotid artery stenting: Is there a difference between proximal occlusion and distal filter?. International Journal of Cardiology, 2015, 187, 592-593.	0.8	3
98	DAPT Duration After Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2017, 10, 1211-1214.	1.1	3
99	Deciding on the Duration of Dual Antiplatelet Therapy—When the Choice Between 2 Evils Is Still Evil. JAMA Cardiology, 2017, 2, 488.	3.0	3
100	Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. European Heart Journal, 2020, 41, 1701-1702.	1.0	3
101	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovascular Drugs and Therapy, 2023, 37, 1031-1038.	1.3	3
102	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. International Journal of Cardiology, 2016, 221, 695-696.	0.8	2
103	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	0.8	2
104	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. EuroIntervention, 2019, 15, e269-e278.	1.4	2
105	Time for science to catch up with clinical practice?. Journal of Thoracic Disease, 2015, 7, E603-6.	0.6	2
106	Cyphering the Mechanism of Late Failure of Bioresorbable Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2015, 8, e95-e97.	1.1	1
107	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2017, 166, 606.	2.0	1
108	Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. Cardiovascular Diagnosis and Therapy, 2017, 7, S102-S106.	0.7	1

#	Article	IF	CITATIONS
109	A kinase anchor protein 121 regulates mitochondrial function and survival in cardiac and smooth muscle cells. Journal of Molecular and Cellular Cardiology, 2007, 42, S81-S82.	0.9	0
110	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. Canadian Journal of Cardiology, 2015, 31, 1205.e5-1205.e6.	0.8	0
111	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?. JACC: Cardiovascular Interventions, 2016, 9, 976-977.	1.1	0
112	Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner?. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 721-724.	0.4	0
113	Bivalirudina frente a heparina no fraccionada en sÃndromes coronarios agudos: ¿hay un vencedor?. Revista Espanola De Cardiologia, 2016, 69, 721-724.	0.6	0
114	Response by Valgimigli and Gargiulo to Letter Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?― Circulation, 2017, 135, e1037-e1038.	1.6	0
115	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. Journal of the American Heart Association, 2017, 6, .	1.6	0
116	Antithrombotic treatment strategies after PCI – Authors' reply. Lancet, The, 2020, 395, 867-868.	6.3	0
117	Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial― Circulation, 2021, 143, e797-e798.	1.6	0
118	Aspirin Monotherapy After BioFreedom Stent and 1-Month DAPT. JACC: Cardiovascular Interventions, 2021, 14, 1812-1814.	1.1	0
119	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	1.4	0
120	The Effects of Cangrelor on Platelet Aggregation in STEMI Patients. JACC: Cardiovascular Interventions, 2022, 15, 229-230.	1.1	0
121	Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. Reviews in Cardiovascular Medicine, 2015, 16, 131-139.	0.5	0
122	Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. Global & Regional Health Technology Assessment, 2022, 9, 17-26.	0.2	0